✉ Email this page to a colleague
« Back to Dashboard
Ruzasvir is an investigational drug.
There have been 10 clinical trials for Ruzasvir. The most recent clinical trial was a Phase 2 trial, which was initiated on January 28th 2015.
The most common disease conditions in clinical trials are Hepatitis C, Hepatitis, and Hepatitis A. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., Atea Pharmaceuticals, Inc., and [disabled in preview].
There are two US patents protecting this investigational drug and thirty-three international patents.
Recent Clinical Trials for Ruzasvir
|A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV||Atea Pharmaceuticals, Inc.||Phase 2|
|Drug-drug Interaction Study of Ruzasvir and Bemnifosbuvir||Atea Pharmaceuticals, Inc.||Phase 1|
|Efficacy and Safety of Uprifosbuvir (MK-3682) + Ruzasvir (MK-8408) in Treating Hepatitis C Virus Infection Genotypes 1-6 (MK-3682-041)||Merck Sharp & Dohme Corp.||Phase 2|
Top disease conditions for Ruzasvir
Top clinical trial sponsors for Ruzasvir
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Ruzasvir||⤷ Try a Trial||Process for preparing substituted tetracyclic heterocycle compounds||Merck Sharp & Dohme Corp. (Rahway, NJ)||⤷ Try a Trial|
|Ruzasvir||⤷ Try a Trial||Heterocycle-substituted tetracyclic compounds and methods of use thereof for the treatment of viral diseases||Merck Sharp & Dohme Corp. (Rahway, NJ)||⤷ Try a Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Ruzasvir||World Intellectual Property Organization (WIPO)||WO2016196932||2035-06-04||⤷ Try a Trial|
|Ruzasvir||Argentina||AR094496||2033-01-16||⤷ Try a Trial|
|Ruzasvir||Australia||AU2013374112||2033-01-16||⤷ Try a Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|